Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of BI 425809 Tablets for 12 Days to Young and Elderly Healthy Male and Female Volunteers and Comparison of Pharmacokinetics of a Single Oral Dose of BI 425809 (Morning Versus Evening)

NCT02337283 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
96
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Boehringer Ingelheim